AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17134946 — intervention group
Group type: COMPARATOR
Intervention: Sham respiratory muscle unloading (placebo)
Number of subjects: 6
Study 14747210 — intervention group
Group type: EXPERIMENTAL
Intervention: cPPG >150 mg/dl
Number of subjects: 1827
Study 14747210 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 1827
Study 14747210 — intervention group
Group type: COMPARATOR
Intervention: Oral agents
Number of subjects: 1827
Study 14747210 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 1827
Study 11487072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid laser treatment
Number of subjects: 46
Study 11487072 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 46
Study 9633066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractal coated electrode (Biotronik SD‐V137)
Number of subjects: 10
Study 9633066 — intervention group
Group type: COMPARATOR
Intervention: Control electrode (TIR-leads with a surface area of 10 mm2 and a 'fractal' coating of titanium nitride)
Number of subjects: 10
Study 9633066 — intervention group
Group type: COMPARATOR
Intervention: Control electrode (TIR-leads)
Number of subjects: 10
Study 7936248 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular stimulation in albinos
Number of subjects: 9
Study 7936248 — intervention group
Group type: COMPARATOR
Intervention: Monocular stimulation in healthy controls
Number of subjects: 9
Study 3169116 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled adenosine at a concentration of 5 mg.ml‐1
Number of subjects: 0
Study 3169116 — intervention group
Group type: COMPARATOR
Intervention: Infusion of a comparable dose of adenosine
Number of subjects: 0
Study 31253145 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plating (surgical treatment with open reduction and internal fixation using volar locking plates)
Number of subjects: 100
Study 31253145 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (closed reduction and plaster immobilization)
Number of subjects: 100
Study 31253145 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar plating
Number of subjects: 100
Study 31253145 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100
Study 28403911 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with monthly social assistance, domotic, and remote assistance
Number of subjects: 320
Study 28403911 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study 25401387 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nutrient supply
Number of subjects: 50
Study 25401387 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrient supply
Number of subjects: 50
Study 22727477 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.5mg
Number of subjects: 49
Study 22727477 — intervention group
Group type: COMPARATOR
Intervention: Control (Healthy Controls)
Number of subjects: 49
Study 21994429 — intervention group
Group type: EXPERIMENTAL
Intervention: U-500R insulin (50 units)
Number of subjects: 24
Study 21994429 — intervention group
Group type: EXPERIMENTAL
Intervention: U-500R insulin (100 units)
Number of subjects: 24
Study 21994429 — intervention group
Group type: COMPARATOR
Intervention: U-100R insulin (50 units)
Number of subjects: 24
Study 21994429 — intervention group
Group type: COMPARATOR
Intervention: U-100R insulin (100 units)
Number of subjects: 24
Study 18337600 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (target BIS range, 40 to 60)
Number of subjects: 2000
Study 18337600 — intervention group
Group type: COMPARATOR
Intervention: ETAG-guided anesthesia (target ETAG range, 0.7 to 1.3 MAC)
Number of subjects: 2000
Study 18337600 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 2000
Study 18337600 — intervention group
Group type: COMPARATOR
Intervention: ETAG-guided anesthesia
Number of subjects: 2000
Study 16600226 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 257
Study 16600226 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 257
Study 12873780 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg of micronized 17beta‐estradiol
Number of subjects: 1612
Study 12873780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1612
Study 10873167 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced inactivated poliovirus vaccine (IPV) administered intramuscularly within 24 hours of birth
Number of subjects: 50
Study 10873167 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccinations only (control group)
Number of subjects: 50
Study 9351723 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding with an immune‐enhancing formula (IEF) via jejunostomy tube, started on postoperative day 1, goal of 25 kcal/kg per day
Number of subjects: 195
Study 9351723 — intervention group
Group type: COMPARATOR
Intervention: Control group (CNTL) receiving intravenous crystalloid solutions
Number of subjects: 195
Study 8471660 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day orally for at least 1 year
Number of subjects: 26
Study 8471660 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (melphalan 15 mg/m2 i.v. and prednisolone 60 mg/m2 orally)
Number of subjects: 26
Study 2431027 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 48/80
Number of subjects: 0
Study 2431027 — intervention group
Group type: COMPARATOR
Intervention: Normal skin sites (control)
Number of subjects: 0
Study 30158069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg, enteric-coated, once daily)
Number of subjects: 12546
Study 30158069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 12546
Study 27805885 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 60
Study 27805885 — intervention group
Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 60
Study 24888818 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial therapy (arm A)
Number of subjects: 595
Study 24888818 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial therapy (arm B)
Number of subjects: 595
Study 24888818 — intervention group
Group type: COMPARATOR
Intervention: Continue initial therapy (arm C1)
Number of subjects: 595
Study 24888818 — intervention group
Group type: COMPARATOR
Intervention: Change to alternative chemotherapy (arm C2)
Number of subjects: 595
Study 24888818 — intervention group
Group type: COMPARATOR
Intervention: Arms C1 and C2 combined
Number of subjects: 595
Study 24888818 — intervention group
Group type: EXPERIMENTAL
Intervention: Arms A, B, and C (C1 and C2 combined)
Number of subjects: 595
Study 22071326 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure (100 μg/m(3))
Number of subjects: 0
Study 22071326 — intervention group
Group type: COMPARATOR
Intervention: Clean air exposure (control)
Number of subjects: 0
Study 20630159 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention (Therapeutic Lifestyle Change diet education tailored to baseline stage of change)
Number of subjects: 501
Study 20630159 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention
Number of subjects: 501
Study 20630159 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 501
Study 18789115 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with a polymyxin B-immobilized fiber column (DHP-PMX)
Number of subjects: 21
Study 15759056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 10141
Study 15759056 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 10141
Study 15759056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin or Unfractionated heparin
Number of subjects: 10141
Study 12583246 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating Western and traditional Chinese medicine (IWTCM) including Chinese medicine and allopurinol
Number of subjects: 136
Study 12583246 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol only (Control group)
Number of subjects: 136
Study 10051723 — intervention group
Group type: EXPERIMENTAL
Intervention: Active regime (hot washing and encasing covers + acaricide)
Number of subjects: 56
Study 7756102 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg DU 29894
Number of subjects: 19
Study 7756102 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg DU 29894
Number of subjects: 19
Study 7756102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flesinoxan
Number of subjects: 19
Study 7756102 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 19
Study 7756102 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sulpiride
Number of subjects: 19
Study 2110678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropical fish diet (500 g/day, rich in arachidonic acid and docosahexaenoic acid)
Number of subjects: 18
Study 2110678 — intervention group
Group type: EXPERIMENTAL
Intervention: Southern fish diet (500 g/day, rich in docosahexaenoic acid)
Number of subjects: 18
Study 2110678 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo meat diet (500 g/day, rich in linoleic and arachidonic acids)
Number of subjects: 18
Study 2110678 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet (low in fat, no 20‐ and 22‐carbon PUFA)
Number of subjects: 18
Study 2110678 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 18
Study 393429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy regimen considering circadian rhythm (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide)
Number of subjects: 63
Study 393429 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy regimen without considering circadian rhythm (methotrexate or 5-FU, followed by vinblastine and cyclophosphamide)
Number of subjects: 63
Study 30370782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulating Play Intervention
Number of subjects: 30
Study 30370782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28356767 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin 1200 mg BID
Number of subjects: 77
Study 28356767 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaifenesin 600 mg BID
Number of subjects: 77
Study 28356767 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 77
Study 28356767 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (for 600 mg)
Number of subjects: 77
Study 25466702 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (2 mg)
Number of subjects: 16
Study 25466702 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 16
Study 25466702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biperiden and citalopram
Number of subjects: 16
Study 25466702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23062170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent depressive symptoms (self-report)
Number of subjects: 361
Study 23062170 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing behaviors (parent report)
Number of subjects: 361
Study 23062170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent depressive and externalizing symptom trajectories
Number of subjects: 361
Study 21426666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine with sorafenib
Number of subjects: 30
Study 21426666 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine with placebo
Number of subjects: 30
Study 19468954 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid supplementation
Number of subjects: 0
Study 17400842 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily for 2 weeks, then 100 mg daily for 4 weeks)
Number of subjects: 99
Study 17400842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical to sertraline)
Number of subjects: 99
Study 15041109 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (FLU) 250 mg t.i.d. p.o.
Number of subjects: 310
Study 15041109 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA) 100 mg t.i.d. p.o.
Number of subjects: 310
Study 14728869 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioadhesive nonoxynol-9 gel
Number of subjects: 240
Study 14728869 — intervention group
Group type: COMPARATOR
Intervention: Nonoxynol-9 suppository
Number of subjects: 240
Study 10195374 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2.0 microg/kg i.v.
Number of subjects: 7
Study 10195374 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP‐2 2.0 microg/kg i.v.
Number of subjects: 7
Study 10195374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyr‐Ala‐HEX 2.0 microg/kg i.v.
Number of subjects: 7
Study 10195374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7756203 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (3 g daily)
Number of subjects: 63
Study 7756203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2184795 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tryptophan diet (160 mg/d for 24 hours) followed by a 16-amino acid drink
Number of subjects: 21
Study 2184795 — intervention group
Group type: COMPARATOR
Intervention: Control testing (placebo)
Number of subjects: 21
Study 399960 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of meglumine ioserinate (single dose)
Number of subjects: 88
Study 399960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of meglumine ioserinate (double dose)
Number of subjects: 88
Study 399960 — intervention group
Group type: EXPERIMENTAL
Intervention: meglumine ioserinate (double dose)
Number of subjects: 88
Study 399960 — intervention group
Group type: EXPERIMENTAL
Intervention: meglumine ioserinate
Number of subjects: 88
Study 31525860 — intervention group
Group type: EXPERIMENTAL
Intervention: SCG DBS (subcallosal cingulate deep brain stimulation)
Number of subjects: 27
Study 31525860 — intervention group
Group type: EXPERIMENTAL
Intervention: SCG DBS
Number of subjects: 27
Study 30449012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 500 IU of hCG in 10 µL culture medium 4 minutes before ET
Number of subjects: 200
Study 30449012 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 10 µL of culture medium alone
Number of subjects: 200
Study 30449012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine infusion of 500 IU of hCG
Number of subjects: 200
Study 28839337 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 441 mg every 4 weeks (n = 35)
Number of subjects: 139
Study 28839337 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 882 mg every 6 weeks (n = 34)
Number of subjects: 139
Study 28839337 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 1064 mg every 8 weeks (n = 70)
Number of subjects: 139
Study 26210693 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 36
Study 26210693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24035461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-based intervention
Number of subjects: 50
Study 22648627 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape extract supplement containing 8 mg resveratrol (Stilvid®)
Number of subjects: 75
Study 22648627 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape extract (GE) without resveratrol
Number of subjects: 75
Study 22648627 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 75
Study 19243707 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term statin treatment for > or =6 months before PCI (statin group, 44 patients)
Number of subjects: 100
Study 19243707 — intervention group
Group type: COMPARATOR
Intervention: No long-term statin treatment (nonstatin group, 56 patients)
Number of subjects: 100
Study 19243707 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term statin treatment for > or =6 months before PCI (statin group)
Number of subjects: 100
Study 19243707 — intervention group
Group type: COMPARATOR
Intervention: No long-term statin treatment (nonstatin group)
Number of subjects: 100
Study 17304422 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 20 mg/kg/d in one dose
Number of subjects: 120
Study 17304422 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 10 mg/kg/d every 12 hours (Control)
Number of subjects: 120
Study 15054662 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly males (EM)
Number of subjects: 35
Study 15054662 — intervention group
Group type: COMPARATOR
Intervention: Young men (YM)
Number of subjects: 35
Study 11575409 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg kg(‐1) h(‐1)
Number of subjects: 8
Study 11575409 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg kg(‐1) h(‐1)
Number of subjects: 8
Study 11575409 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg(‐1) h(‐1)
Number of subjects: 8
Study 11575409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9880204 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + Prazosin 1 mg
Number of subjects: 17
Study 9880204 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine 30 mg + Isosorbide dinitrate 30 mg
Number of subjects: 17
Study 7972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training program for lower extremities
Number of subjects: 5
Study 30654854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 36
Study 30654854 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 36
Study 29081250 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training (LT)
Number of subjects: 0
Study 29081250 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity locomotor training (LT)
Number of subjects: 0
Study 25803018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Capsule Endoscopy (VCE)
Number of subjects: 79
Study 25803018 — intervention group
Group type: COMPARATOR
Intervention: Push Enteroscopy (PE)
Number of subjects: 79
Study 25131239 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach (MV)
Number of subjects: 1188
Study 21622538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate-amodiaquine
Number of subjects: 56
Study 21622538 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 56
Study 19369828 — intervention group
Group type: EXPERIMENTAL
Intervention: Physically active (n = 511)
Number of subjects: 937
Study 19369828 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (n = 212)
Number of subjects: 937
Study 16422753 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment (RCT)
Number of subjects: 76
Study 16422753 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (FU)
Number of subjects: 76
Study 15630340 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 0
Study 15630340 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E
Number of subjects: 0
Study 15630340 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 0
Study 15630340 — intervention group
Group type: COMPARATOR
Intervention: Retinal, retinyl palmitate, N-acetyl cysteine, Isotretinoin
Number of subjects: 0
Study 11529827 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone sodium succinate on anesthetic induction (n = 6)
Number of subjects: 13
Study 11529827 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 13
Study 9382758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa 5142/1210-Flagella Vaccine IMMUNO
Number of subjects: 400
Study 9382758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 8516538 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (IS‐5‐MN) 40 mg/12 hours from day 6 to 20, then 40 mg/8 hours from day 21 to 100
Number of subjects: 20
Study 8516538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2897303 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol 10 mg
Number of subjects: 9
Study 2897303 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 40 mg
Number of subjects: 9
Study 2897303 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 31903689 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-directed face-to-face therapy (n = 26)
Number of subjects: 79
Study 31903689 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepractice therapy via 'SwallowIT' (n = 26)
Number of subjects: 79
Study 31903689 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-directed therapy (n = 27)
Number of subjects: 79
Study 31903689 — intervention group
Group type: COMPARATOR
Intervention: SwallowIT and clinician-directed models
Number of subjects: 79
Study 29535646 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Motional Training(R)
Number of subjects: 60
Study 29535646 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 60
Study 26529471 — intervention group
Group type: EXPERIMENTAL
Intervention: Four counseling sessions over 7 weeks with a message of sit less and move more
Number of subjects: 35
Study 26529471 — intervention group
Group type: COMPARATOR
Intervention: Calcium for bone health (attention‐matched control group)
Number of subjects: 35
Study 26529471 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study 24570011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultravision™ (device on)
Number of subjects: 30
Study 24570011 — intervention group
Group type: COMPARATOR
Intervention: Control (device off)
Number of subjects: 30
Study 22515895 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus with matched‐taper single‐cone technique
Number of subjects: 90
Study 22515895 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaSEAL with matched‐taper single‐cone technique
Number of subjects: 90
Study 22515895 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus with lateral condensation technique
Number of subjects: 90